Sponsor:
Medicenna Therapeutics, Inc.
Code:
NCT05086692
Conditions
Advanced Solid Tumor
Unresectable Solid Tumor
Clear Cell Renal Cell Carcinoma
Triple Negative Breast Cancer
Non-Small Cell Lung Cancer Squamous
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MDNA11
Pembrolizumab (KEYTRUDA®)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-07. This information was provided to ClinicalTrials.gov by Medicenna Therapeutics, Inc. on 2025-07-09.